AD

Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD

Retrieved on: 
Tuesday, October 24, 2023
AD, Alzheimer's disease, Repeatable Battery for the Assessment of Neuropsychological Status, Vaccine, Meningoencephalitis, Prevalence, Dementia, Research, HIV disease progression rates, Test management, Alzheimer's Association, Cerebral amyloid angiopathy, Mini–Mental State Examination, Disease, Ace, MMSE, Swelling, Assessment, TMT, Emerging technologies, Patient, CAA, Pharmaceutical industry, Medical imaging

Araclon gave a late-breaking presentation at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference.

Key Points: 
  • Araclon gave a late-breaking presentation at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference.
  • Data confirm preliminary findings indicating a comparable safety profile between ABvac40 and placebo groups, with similar rates of treatment-emergent adverse events.
  • In addition, volumetric magnetic resonance imaging showed a lesser increase in whole brain atrophy in the ABvac40 group vs placebo.
  • The results reported for ABvac40 to date validate its clinical potential, positioning it as promising therapeutic candidate for early AD treatment.

ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis

Retrieved on: 
Tuesday, October 24, 2023
Standard of care, AD, George Washington University School of Medicine & Health Sciences, Clinical trial, Outline of health sciences, Internet, Physician, Congress, MD, Research, Contract research organization, Dupilumab, Drug development, Addiction severity index, European Academy of Allergy and Clinical Immunology, Disease, Webcast, ASLN, EASI, UCLA, Atopic dermatitis, Patient, Pharmaceutical industry, Dermatology, Venereology

During the event, ASLAN will present additional analyses of the TREK-AD patient population building on data recently published at the 32nd European Academy of Dermatology and Venereology (EADV) Congress.

Key Points: 
  • During the event, ASLAN will present additional analyses of the TREK-AD patient population building on data recently published at the 32nd European Academy of Dermatology and Venereology (EADV) Congress.
  • ASLAN will also present new insights on the AD treatment landscape based on a recently conducted survey of physicians and AD patients in the US.
  • “We are pleased to be contributing to today’s discussion that aims to spark a dialogue on the changing AD patient profile that presents in clinical studies.
  • Register here to attend the webcast or watch the replay of the event, which will be available for 180 days.

NeuroTherapia Presents Clinical Data from Phase 1b Clinical Trial of NTRX-07 for the Treatment of Alzheimer’s Disease

Retrieved on: 
Tuesday, October 24, 2023
Plasma, AD, Biotechnology, CNS, Clinical trial, ADAS-Cog, Neuroinflammation, EEG, Quantitative electroencephalography, Patient, Central nervous system, Pharmaceutical industry

CLEVELAND, Oct. 24, 2023 (GLOBE NEWSWIRE) -- NeuroTherapia, Inc., a clinical-stage, privately held biotechnology company developing oral, small molecule drugs to address neuroinflammatory conditions of the central nervous system (CNS), today announced the presentation of clinical data from its Phase 1b clinical trial of NTRX-07, an oral, small molecule CB2-targeting therapy in development for the treatment of Alzheimer’s disease (AD), in healthy volunteers and a subset of patients with mild cognitive impairment or early AD, at the Clinical Trials on Alzheimer’s Disease (CTAD) conference, taking place in Boston, Mass., Oct. 24-27, 2023.

Key Points: 
  • The early signs of clinical activity we observed in the AD patients included in the study were even more encouraging.
  • 32 participants, including one cohort of 8 patients with early-stage AD, received NTRX-07 or a placebo for seven days in a double-blind, randomized clinical study.
  • The safety profile of NTRX-07 supports further clinical development, with no dose-limiting or serious adverse events observed during the trial.
  • "This data gives us additional confidence that NTRX-07 could become a valuable treatment option and based on its safety profile, could be used in combination with approved antibody treatments.”

NKGen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease

Retrieved on: 
Tuesday, October 24, 2023
FDA, AD, IND, Food, Biomarker, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, WCN, Protein, Cerebrospinal fluid, Traffic barrier, Neuroinflammation, AAIC, NK, Patient, Pharmaceutical industry

SANTA ANA, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for SNK01 natural killer (NK) cell therapy for treatment of moderate Alzheimer’s Disease (AD). SNK01 is an autologous, non-genetically modified NK cell product that has enhanced cytotoxicity and activating receptor expression.

Key Points: 
  • SANTA ANA, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for SNK01 natural killer (NK) cell therapy for treatment of moderate Alzheimer’s Disease (AD).
  • SNK01 is an autologous, non-genetically modified NK cell product that has enhanced cytotoxicity and activating receptor expression.
  • NKGen’s SNK01 program continues to show positive progress in Alzheimer’s Disease, as demonstrated by results reported in recent poster presentations in July and October 2023 at AAIC and WCN, respectively.
  • “This represents a pivotal milestone for our company and our neurodegenerative disease program,” said Paul Y.

Sandy Spring Bancorp Reports Third Quarter Earnings of $20.7 Million

Retrieved on: 
Tuesday, October 24, 2023
Insurance, Sale, Growth, AD, Real estate, Federal Reserve Bank of St. Louis, Website, Recession, National Keelung Commercial & Industrial Vocational Senior High School, Mortality, News, Sandy Spring Bank, GAAP, Acquisition, Federal Reserve Bank, Environment, Webcast, Marketing, Commercial, FHLB, Probability, Life insurance, Video game, Renewable energy, Rare-earth element, Bank, FDIC, Washington metropolitan area

Current quarter core earnings were $27.8 million ($0.62 per diluted common share), compared to $27.1 million ($0.60 per diluted common share) for the quarter ended June 30, 2023 and $35.7 million ($0.80 per diluted common share) for the quarter ended September 30, 2022.

Key Points: 
  • Current quarter core earnings were $27.8 million ($0.62 per diluted common share), compared to $27.1 million ($0.60 per diluted common share) for the quarter ended June 30, 2023 and $35.7 million ($0.80 per diluted common share) for the quarter ended September 30, 2022.
  • Net interest income for the third quarter of 2023 declined $5.4 million or 6% compared to the previous quarter and $27.9 million or 25% compared to the third quarter of 2022.
  • Provision for credit losses directly attributable to the funded loan portfolio for the current quarter was $3.2 million compared to $4.5 million in the previous quarter and $14.1 million in the prior year quarter.
  • Total net charge-offs for the current quarter amounted to $0.1 million compared to $1.8 million for the second quarter of 2023 and $0.5 million of net recoveries for the third quarter of 2022.

Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated Dose

Retrieved on: 
Monday, October 23, 2023
Alzheimer's Disease Cooperative Study, Element, Cognition, Plasma, Euronext Amsterdam, AD, Alzheimer's disease, ADCS, BID, Skin, Hepatology, OLE, European, Probability, University, VIVA, Safety, Therapy, Patient, Memory, DSMB, Pharmaceutical industry, Neuroscience

VIVA-MIND (NCT03919162) is an ongoing Phase 2 study for varoglutamstat conducted in the U.S., complementary to Vivoryon’s VIVIAD Phase 2b study being conducted in Europe.

Key Points: 
  • VIVA-MIND (NCT03919162) is an ongoing Phase 2 study for varoglutamstat conducted in the U.S., complementary to Vivoryon’s VIVIAD Phase 2b study being conducted in Europe.
  • The primary endpoint of the study is evaluating Clinical Dementia Rating scale Sum of Boxes (CDR-SB) over a 72-week treatment period.
  • “We are thrilled to report this new important and validating element of our rigorously and meticulously designed program for varoglutamstat.
  • Vivoryon remains on track to report the final data readout from the VIVIAD study in the first quarter of 2024.

Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting

Retrieved on: 
Thursday, October 19, 2023
Week, Alzheimer's disease, Amyloid, Patient, AD, Biogen, Clarity, MAPT, HIV disease progression rates, Clinical trial, BIIB, PET, LTE, Caregiver, CLARITY, Biomarker, Safety, Pharmaceutical industry, Medical imaging

CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its Alzheimer’s disease portfolio at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) meeting taking place October 24-27 in Boston, Mass.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its Alzheimer’s disease portfolio at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) meeting taking place October 24-27 in Boston, Mass.
  • The presentations will advance the understanding of Alzheimer’s disease with data on different treatment approaches, predictive analysis of disease progression, and clinical meaningfulness of amyloid removal for patients and their caregivers.
  • The presentation will include the latest data from the CLARITY AD optional tau PET longitudinal sub-study.
  • Oral presentation: Precision medicine analysis of heterogeneity in individual-level treatment response to beta-amyloid removal in early Alzheimer’s disease: Thursday, October 26, 4:35 p.m.

ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis

Retrieved on: 
Wednesday, October 18, 2023
ET, AD, George Washington University School of Medicine & Health Sciences, Clinical trial, Outline of health sciences, MPH, Internet, Contract research organization, Webcast, ASLN, UCLA, Atopic dermatitis, Patient, UCLA Health, Nightclub, Pharmaceutical industry, MD, Doctor of Philosophy

Register here to attend the webinar event on October 24, 2023 at 11:00 am ET

Key Points: 
  • Register here to attend the webinar event on October 24, 2023 at 11:00 am ET
    SAN MATEO, Calif. and SINGAPORE, Oct. 18, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will co-host a panel discussion with a leading Clinical Research Organization (CRO), “The Changing Face of Atopic Dermatitis: How the Clinical Trial and Treatment Landscape Has Changed in the Seven Years Following Dupilumab’s Introduction”, that will feature Key Opinion Leaders (KOLs) Jonathan Silverberg, MD, PhD, MPH (The George Washington University School of Medicine and Health Sciences), and April W. Armstrong, MD, MPH (UCLA Health).
  • The webinar event will include presentations by ASLAN and the CRO followed by a panel discussion with both KOLs, on the changes in the clinical trial and treatment landscape in atopic dermatitis (AD), the impact these changes have on clinical data and new therapies, and potential solutions for optimizing AD trials.
  • ASLAN management will discuss data from the Phase 2b TREK-AD study of eblasakimab and will present new market research from surveys of AD patients and prescribers on their views of current and future therapies.
  • Register here to attend the webcast from 11:00 am – 12:00 pm ET on Tuesday, October 24, 2023, or watch the replay of the event.

Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy

Retrieved on: 
Wednesday, October 25, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Medicare Part D, Patient, AD, AFL, UCL Queen Square Institute of Neurology, University College London, Biomarker, Therapy, Fluid mechanics, CSF, Medication, Regeneron Pharmaceuticals, Alnylam Pharmaceuticals, Gene silencing, CNS, Clinical trial, APP, ALNY, Cerebral amyloid angiopathy, Cerebrospinal fluid, RNA interference, ALN, Brain, Safety, CAA, Peptide, Central nervous system, Medical device, Pharmaceutical industry

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced additional positive interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy (CAA).

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced additional positive interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy (CAA).
  • The data were presented today in a late-breaker session at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) conference, being held October 24-27, 2023, in Boston, MA.
  • “Today’s results showcase the exciting emerging profile of ALN-APP.
  • In this study to date, blinded single doses of ALN-APP, which are administered by intrathecal injection, have been well tolerated.

C2N Diagnostics Introduces Next-Generation Fluid Biomarker to the Field of Alzheimer’s Disease: Test to Help Researchers Track Neurofibrillary “Tau” Tangle Pathology

Retrieved on: 
Wednesday, October 25, 2023
Biotechnology, Health, General Health, Pharmaceutical, Neurology, Mental Health, Health Technology, Research, Genetics, Science, Clinical Trials, PSP, Ageing, AD, CSR, Biomarker, Washington University in St. Louis, Therapy, CBD, Lund University, Pathology, Non-fungible token, PET, RUO, Washington University School of Medicine, Partnership, Risk assessment, DRS, Frontotemporal dementia, Brain, Diagnosis, Technology management, FTD, Corticobasal degeneration, Nature Medicine, Medical imaging, Medical device

The MTBR-tau fluid biomarker can be used in the diagnosis of AD, in disease staging, and in the development of tau-directed therapeutics.

Key Points: 
  • The MTBR-tau fluid biomarker can be used in the diagnosis of AD, in disease staging, and in the development of tau-directed therapeutics.
  • The RUO test availability allows leading industry and clinician researchers to further study ways to better diagnose, monitor investigational treatment responses, and understand AD’s underlying biological mechanisms.
  • Dr. David M. Holtzman, the Barbara Burton and Reuben M. Morriss III Distinguished Professor of Neurology, co-founded C2N with Dr. Bateman.
  • C2N is a leader in advancing innovative clinical diagnostics to improve the early diagnosis and treatment of Alzheimer’s disease, and our collaboration enables Washington University discoveries to become commercialized globally.”